Literature DB >> 27473082

A novel VHLα isoform inhibits Warburg effect via modulation of PKM splicing.

Yanbin Liu1, Haixia Yang2, Lin Li2, She Chen2, Feifei Zuo2, Liang Chen3.   

Abstract

Von Hippel-Lindau (VHL) is the most frequently mutated gene in clear cell renal carcinoma. Here, we identified a novel translational variant of VHL, termed VHLα, initiated from an alternative translational start site upstream and in frame with the ATG start codon. We showed that VHLα interacts with and regulates heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1), which consequently modulates pyruvate kinase transcript splicing and reprograms cellular glucose metabolism. Our study demonstrated that a novel VHL isoform may function as a tumor suppressor through inhibiting the Warburg effect.

Entities:  

Keywords:  Alternative translation; Glucose metabolism; Pyruvate kinase; VHL; hnRNPA2B1

Mesh:

Substances:

Year:  2016        PMID: 27473082     DOI: 10.1007/s13277-016-5191-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  43 in total

Review 1.  hnRNP complexes: composition, structure, and function.

Authors:  A M Krecic; M S Swanson
Journal:  Curr Opin Cell Biol       Date:  1999-06       Impact factor: 8.382

Review 2.  Initiation of translation in prokaryotes and eukaryotes.

Authors:  M Kozak
Journal:  Gene       Date:  1999-07-08       Impact factor: 3.688

3.  Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein.

Authors:  Miguel A Esteban; Sarah K Harten; Maxine G Tran; Patrick H Maxwell
Journal:  J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 10.121

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  A conserved family of prolyl-4-hydroxylases that modify HIF.

Authors:  R K Bruick; S L McKnight
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

6.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

7.  Specific genetic change in tumors associated with von Hippel-Lindau disease.

Authors:  K Tory; H Brauch; M Linehan; D Barba; E Oldfield; M Filling-Katz; B Seizinger; Y Nakamura; R White; F F Marshall
Journal:  J Natl Cancer Inst       Date:  1989-07-19       Impact factor: 13.506

8.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

9.  HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase.

Authors:  Ataman Sendoel; Ines Kohler; Christof Fellmann; Scott W Lowe; Michael O Hengartner
Journal:  Nature       Date:  2010-06-03       Impact factor: 49.962

10.  The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth.

Authors:  Bernhard Schermer; Cristina Ghenoiu; Malte Bartram; Roman Ulrich Müller; Fruzsina Kotsis; Martin Höhne; Wolfgang Kühn; Manuela Rapka; Roland Nitschke; Hanswalter Zentgraf; Manfred Fliegauf; Heymut Omran; Gerd Walz; Thomas Benzing
Journal:  J Cell Biol       Date:  2006-11-13       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.